Article -> Article Details
| Title | Cannabidiol Market Analysis, Size, Share, Trends, Growth and Outlook Report 2025-2033 |
|---|---|
| Category | Business --> Healthcare |
| Meta Keywords | Cannabidiol Market |
| Owner | Imarc |
| Description | |
| Market Overview The global cannabidiol market was valued at USD 7.0 Billion in 2024 and is forecast to reach USD 24.4 Billion by 2033, growing at a CAGR of 14.84% during 2025-2033. North America leads the market with over 40.4% share in 2024, driven by legalization, consumer awareness, and product innovation. The market growth is boosted by therapeutic demand, regulatory support, and widespread adoption in various products. Study Assumption Years
Cannabidiol Market Key Takeaways
Sample Request Link: https://www.imarcgroup.com/cannabidiol-market/requestsample Market Growth Factors The global cannabidiol market increases because consumers grow more aware of CBD's medical benefits. Chronic diseases such as insomnia, anxiety, and pain management occur at a high rate because of unhealthy lifestyles and diets so this is expected to drive the market. For example, in 2024, 43% of American adults reported having increased feelings of anxiety in comparison to 2023. CBD products stay popular. Worldwide, cannabis-derived products have legal status for medical use and recreational use which supports market growth, supports manufacturing, and supports consumer trust. Further growth has been linked to the increased use of CBD in product segments including beverages, skin and beauty products, and dietary supplements, and to the growth of U.S. hemp supply chains as a result of the U.S. Farm Bill. CBD is on the market within animal health, expanding the addressable market into veterinary medicine. Manufacturers and retailers form partnerships, and research and development (R&D) activities gain priority to create products for medicinal or recreational purposes. Laws also influence the market as countries like the United States, Canada, and Germany legislate changes to cannabis laws to regulate and legalize CBD. For example, in 2024 Germany decriminalized the possession and cultivation of marijuana, and products containing CBD became more widely available for the public. Consumers increasingly accept CBD, its medicinal efficacy is evidenced by growing scientific study, the FDA approved drugs like Epidiolex, and existing companies introduce new CBD-infused products (edibles, cosmetics, etc.) with CBD-based wellness products so trust in its safety and efficacy to treat anxiety, pain, inflammation, epilepsy, and other conditions grew. Market Segmentation By Product:
By Source Type:
By Grade:
By Sales Type:
Regional Insights North America dominates the cannabidiol market with a 40.4% share in 2024, driven by progressive regulations that support CBD manufacturing, sales, and consumption. The U.S. represents over 82.8% of this market segment, bolstered by legalization such as the 2018 Farm Bill, consumer health trends, and significant investments in CBD product innovation and distribution networks. These factors create a favorable environment fostering ongoing growth and market leadership. Recent Developments & News
Key Players
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization. Request For Customization: https://www.imarcgroup.com/request?type=report&id=12764&flag=E About Us IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research. Contact Us IMARC Group 134 N 4th St. Brooklyn, NY 11249, USA Email: sales@imarcgroup.com Tel No: (D) +91 120 433 0800 United States: +1-201971-6302 | |